<p>Axsome Therapeutics, Inc.（纳斯达克代码：AXSM - 获取免费报告）首席运营官 Mark Jacobson 于 5 月 5 日（星期二）出售了 233 股公司的股票。股票以平均价格 228.18 美元出售，总价值为 53,165.94 美元。交易完成后，首席运营官在公司持有 4,517 股，价值 1,030,689.06 美元。这代表其持股减少了 4.91%。此次出售在提交给证券交易委员会的文件中披露，您可以通过此链接访问该文件。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<h2>Axsome Therapeutics 股票下跌 0.3%</h2>
<ul>
<li>生物技术行业正在升温——这两只火热股票脱颖而出</li>
</ul>
<p>AXSM 的股票在星期二的交易时段下跌了 0.64 美元，达到 223.06 美元。该公司的股票交易量为 1,019,532 股，而其平均交易量为 882,597 股。该公司的市值为 114.7 亿美元，市盈率为-59.80，贝塔值为 0.59。Axsome Therapeutics, Inc.的 1 年最低价为 96.09 美元，1 年最高价为 234.29 美元。该公司的速动比率为 1.48，流动比率为 1.55，债务与股本比率为 1.38。该公司的 50 日移动平均线为 171.73 美元，200 日移动平均线为 163.34 美元。</p>
<p>Axsome Therapeutics（纳斯达克代码：AXSM - 获取免费报告）于 5 月 4 日（星期一）发布了最新的财报。公司报告本季度每股收益为（1.26 美元），低于分析师一致预期的（0.85 美元），差距为（0.41 美元）。该季度的营业收入为 1.912 亿美元，而分析师预期为 1.911 亿美元。Axsome Therapeutics 的净利润率为-26.59%，股本回报率为-246.90%。该公司的季度收入同比增长 57.4%。整体来看，研究分析师预测 Axsome Therapeutics, Inc.在当前财政年度将发布-1.05 的每股收益。</p>
<h2>分析师评级变动</h2>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>AXSM 最近成为几份研究报告的主题。TD Cowen 在周五的研究报告中重申了对 Axsome Therapeutics 股票的 “买入” 评级。Wolfe Research 在 2 月 23 日（星期一）的研究报告中开始覆盖 Axsome Therapeutics。他们给予该公司 “跑赢大盘” 的评级，并设定 230.00 美元的目标价。加拿大皇家银行在周二的研究报告中将 Axsome Therapeutics 的目标价从 242.00 美元上调至 302.00 美元，并给予该公司 “跑赢大盘” 的评级。Oppenheimer 在周一的研究报告中设定了 280.00 美元的目标价。最后，Jefferies Financial Group 在周一将 Axsome Therapeutics 的目标价从 245.00 美元上调至 275.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股票给予了强烈买入评级，十八位分析师给予买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，Axsome Therapeutics 的共识评级为 “适度买入”，平均目标价为 251.89 美元。</p>
<p><strong>查看我们对 AXSM 的最新分析</strong></p>
<h2>更多 Axsome Therapeutics 新闻</h2>
<ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p>以下是本周影响 Axsome Therapeutics 的关键新闻：</p>
<ul>
<li>积极情绪：强劲的顶线增长——第一季度净产品收入为 1.912 亿美元，同比增长约 57%，主要得益于 AUVELITY（1.532 亿美元）和 SUNOSI（3390 万美元）；这验证了 Axsome 主要产品的商业吸引力。Axsome 2026 年第一季度财务结果</li>
<li>积极情绪：今天多位分析师上调了目标价（特别是瑞穗证券至 310 美元，富国银行至 255 美元，贝尔德至 246 美元，摩根士丹利至 242 美元），持续的 “买入/跑赢大盘” 覆盖增加了预期上行空间并支持近期情绪。分析师覆盖与目标价变动</li>
<li>积极情绪：管道和公司催化剂仍在发挥作用——AUVELITY 获得阿尔茨海默症激动症的批准，AXS-12（猝倒症）的 NDA 提交，AXS-20 的加入——这些可以推动中长期的上行空间。业务更新与管道亮点</li>
<li>中性情绪：管理层外联：Axsome 将参加多个投资者会议（美银的炉边聊天等）——对额外披露有帮助，但时机/影响不确定。投资者会议参与</li>
<li>中性情绪：完整的财报和电话会议记录可供深入阅读；分析师和评论员正在详细分析顺序趋势和指导。财报电话会议记录与分析</li>
<li>消极情绪：财报未达预期：GAAP 每股收益为（1.26 美元），而共识预期为（约 0.85 美元亏损）——更大的亏损和负利润率/股本回报率引发了对近期盈利能力的担忧，尽管收入强劲。第一季度亏损扩大；收入激增（Zacks）</li>
<li>消极情绪：对可持续性的怀疑——评论指出关键产品的销售出现顺序下滑，并对管理层长期峰值收入目标的可实现性提出质疑，这可能会抑制热情。财报回顾与怀疑（Seeking Alpha）</li>
</ul>
<h2>机构投资者对 Axsome Therapeutics 的看法</h2>
<p>一些大型投资者最近增加或减少了对该股票的持股。伊利诺伊州市政退休基金在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 884,000 美元。Hillsdale Investment Management Inc.在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 9,019,000 美元。Fifth Third Bancorp 在第一季度将其在 Axsome Therapeutics 的持股增加了 554.6%。Fifth Third Bancorp 现在拥有 16,214 股该公司的股票，价值 2,741,000 美元，此前在此期间又购买了 13,737 股。汇丰控股 PLC 在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 11,589,000 美元。最后，住友三井信托集团在第一季度将其在 Axsome Therapeutics 的持股增加了 6.8%。住友三井信托集团现在拥有 2,030 股该公司的股票，价值 343,000 美元，此前在此期间又购买了 130 股。机构投资者持有该公司 81.49% 的股票。</p>
<h2>Axsome Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在解决抑郁症、偏头痛、嗜睡症和纤维肌痛等领域未满足的医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制并改善患者的治疗效果。</p>
<p>Axsome 的产品管线包括多个晚期和已批准的候选产品。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们认为比 Axsome Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>Axsome Therapeutics 首席运营官 Mark Jacobson 出售了 233 股股票，平均价格为 228.18 美元，总计 53,165.94 美元。出售后，他持有 4,517 股，价值 1,030,689.06 美元，持股比例减少了 4.91%。该交易已向美国证券交易委员会（SEC）披露。公司的股票下跌 0.3%，报 223.06 美元，市值为 114.7 亿美元。Axsome 报告季度每股亏损 1.26 美元，未达到预期，但收入同比增长 57.4%，达到 1.912 亿美元。分析师维持 “适度买入” 的共识评级，平均目标价为 251.89 美元</p>

<p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the company's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.（纳斯达克代码：AXSM - 获取免费报告）首席运营官 Mark Jacobson 于 5 月 5 日（星期二）出售了 233 股公司的股票。股票以平均价格 228.18 美元出售，总价值为 53,165.94 美元。交易完成后，首席运营官在公司持有 4,517 股，价值 1,030,689.06 美元。这代表其持股减少了 4.91%。此次出售在提交给证券交易委员会的文件中披露，您可以通过此链接访问该文件。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><h2>Axsome Therapeutics Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股票下跌 0.3%</h2>
</div><ul>
<li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术行业正在升温——这两只火热股票脱颖而出</li>
</ul>
</div><p>Shares of AXSM traded down $0.64 during trading hours on Tuesday, reaching $223.06. The company's stock had a trading volume of 1,019,532 shares, compared to its average volume of 882,597. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $234.29. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average of $171.73 and a two-hundred day moving average of $163.34.</p>
<div class="lb-trans"><p>AXSM 的股票在星期二的交易时段下跌了 0.64 美元，达到 223.06 美元。该公司的股票交易量为 1,019,532 股，而其平均交易量为 882,597 股。该公司的市值为 114.7 亿美元，市盈率为-59.80，贝塔值为 0.59。Axsome Therapeutics, Inc.的 1 年最低价为 96.09 美元，1 年最高价为 234.29 美元。该公司的速动比率为 1.48，流动比率为 1.55，债务与股本比率为 1.38。该公司的 50 日移动平均线为 171.73 美元，200 日移动平均线为 163.34 美元。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The company's revenue for the quarter was up 57.4% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（纳斯达克代码：AXSM - 获取免费报告）于 5 月 4 日（星期一）发布了最新的财报。公司报告本季度每股收益为（1.26 美元），低于分析师一致预期的（0.85 美元），差距为（0.41 美元）。该季度的营业收入为 1.912 亿美元，而分析师预期为 1.911 亿美元。Axsome Therapeutics 的净利润率为-26.59%，股本回报率为-246.90%。该公司的季度收入同比增长 57.4%。整体来看，研究分析师预测 Axsome Therapeutics, Inc.在当前财政年度将发布-1.05 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>AXSM has been the subject of several recent research reports. TD Cowen reissued a &#34;buy&#34; rating on shares of Axsome Therapeutics in a research note on Friday. Wolfe Research initiated coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They issued an &#34;outperform&#34; rating and a $230.00 price target for the company. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday. Finally, Jefferies Financial Group boosted their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $251.89.</p>
<div class="lb-trans"><p>AXSM 最近成为几份研究报告的主题。TD Cowen 在周五的研究报告中重申了对 Axsome Therapeutics 股票的 “买入” 评级。Wolfe Research 在 2 月 23 日（星期一）的研究报告中开始覆盖 Axsome Therapeutics。他们给予该公司 “跑赢大盘” 的评级，并设定 230.00 美元的目标价。加拿大皇家银行在周二的研究报告中将 Axsome Therapeutics 的目标价从 242.00 美元上调至 302.00 美元，并给予该公司 “跑赢大盘” 的评级。Oppenheimer 在周一的研究报告中设定了 280.00 美元的目标价。最后，Jefferies Financial Group 在周一将 Axsome Therapeutics 的目标价从 245.00 美元上调至 275.00 美元，并给予该公司 “买入” 评级。一位研究分析师对该股票给予了强烈买入评级，十八位分析师给予买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，Axsome Therapeutics 的共识评级为 “适度买入”，平均目标价为 251.89 美元。</p>
</div><p><strong>View Our Latest Analysis on AXSM</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AXSM 的最新分析</strong></p>
</div><h2>More Axsome Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Axsome Therapeutics 新闻</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p>Here are the key news stories impacting Axsome Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Axsome Therapeutics 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results</li>
<li>Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage &amp; Price Target Moves</li>
<li>Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update &amp; Pipeline Highlights</li>
<li>Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation</li>
<li>Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript &amp; Analysis</li>
<li>Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)</li>
<li>Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review &amp; Skepticism (Seeking Alpha)</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：强劲的顶线增长——第一季度净产品收入为 1.912 亿美元，同比增长约 57%，主要得益于 AUVELITY（1.532 亿美元）和 SUNOSI（3390 万美元）；这验证了 Axsome 主要产品的商业吸引力。Axsome 2026 年第一季度财务结果</li>
<li>积极情绪：今天多位分析师上调了目标价（特别是瑞穗证券至 310 美元，富国银行至 255 美元，贝尔德至 246 美元，摩根士丹利至 242 美元），持续的 “买入/跑赢大盘” 覆盖增加了预期上行空间并支持近期情绪。分析师覆盖与目标价变动</li>
<li>积极情绪：管道和公司催化剂仍在发挥作用——AUVELITY 获得阿尔茨海默症激动症的批准，AXS-12（猝倒症）的 NDA 提交，AXS-20 的加入——这些可以推动中长期的上行空间。业务更新与管道亮点</li>
<li>中性情绪：管理层外联：Axsome 将参加多个投资者会议（美银的炉边聊天等）——对额外披露有帮助，但时机/影响不确定。投资者会议参与</li>
<li>中性情绪：完整的财报和电话会议记录可供深入阅读；分析师和评论员正在详细分析顺序趋势和指导。财报电话会议记录与分析</li>
<li>消极情绪：财报未达预期：GAAP 每股收益为（1.26 美元），而共识预期为（约 0.85 美元亏损）——更大的亏损和负利润率/股本回报率引发了对近期盈利能力的担忧，尽管收入强劲。第一季度亏损扩大；收入激增（Zacks）</li>
<li>消极情绪：对可持续性的怀疑——评论指出关键产品的销售出现顺序下滑，并对管理层长期峰值收入目标的可实现性提出质疑，这可能会抑制热情。财报回顾与怀疑（Seeking Alpha）</li>
</ul>
</div><h2>Institutional Investors Weigh In On Axsome Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Axsome Therapeutics 的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund bought a new stake in Axsome Therapeutics during the first quarter worth approximately $884,000. Hillsdale Investment Management Inc. bought a new stake in Axsome Therapeutics during the first quarter worth approximately $9,019,000. Fifth Third Bancorp boosted its position in Axsome Therapeutics by 554.6% during the first quarter. Fifth Third Bancorp now owns 16,214 shares of the company's stock worth $2,741,000 after purchasing an additional 13,737 shares during the period. Hsbc Holdings PLC bought a new stake in Axsome Therapeutics during the first quarter worth approximately $11,589,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Axsome Therapeutics by 6.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030 shares of the company's stock worth $343,000 after purchasing an additional 130 shares during the period. Institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对该股票的持股。伊利诺伊州市政退休基金在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 884,000 美元。Hillsdale Investment Management Inc.在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 9,019,000 美元。Fifth Third Bancorp 在第一季度将其在 Axsome Therapeutics 的持股增加了 554.6%。Fifth Third Bancorp 现在拥有 16,214 股该公司的股票，价值 2,741,000 美元，此前在此期间又购买了 13,737 股。汇丰控股 PLC 在第一季度购买了 Axsome Therapeutics 的新股份，价值约为 11,589,000 美元。最后，住友三井信托集团在第一季度将其在 Axsome Therapeutics 的持股增加了 6.8%。住友三井信托集团现在拥有 2,030 股该公司的股票，价值 343,000 美元，此前在此期间又购买了 130 股。机构投资者持有该公司 81.49% 的股票。</p>
</div><h2>Axsome Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于开发针对中枢神经系统（CNS）疾病的新疗法。该公司专注于小分子药物，旨在解决抑郁症、偏头痛、嗜睡症和纤维肌痛等领域未满足的医疗需求。Axsome 采用精准医学的方法，利用药理创新来针对疾病的潜在机制并改善患者的治疗效果。</p>
</div><p>Axsome's pipeline includes several late-stage and approved product candidates.</p>
<div class="lb-trans"><p>Axsome 的产品管线包括多个晚期和已批准的候选产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Axsome Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Market Beat

Axsome Therap

加拿大皇家银行

奥本海默控股

Jefferies Financial

Mizuho Financial Group, Inc.

瑞穗金融集团

富国银行

摩根士丹利

美国银行

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

内幕交易：Axsome Therapeutics（NASDAQ:AXSM）的首席运营官出售了 233 股股票